Hematopoietic Cell Transplantation for Testicular Cancer — CPB 0617 | AETNA Coverage Update

Aetna modified CPB 0617, its hematopoietic cell transplantation for testicular cancer coverage policy, effective December 5, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0617 governing autologous hematopoietic cell transplantation (HCT) for testicular cancer. The revision clarifies medical necessity criteria across three covered indications and draws a hard line around two scenarios Aetna considers experimental. CPT codes 38241 (autologous HPC transplantation) and the full 38206–38230 stem cell services family are the primary codes affected. If your practice or facility bills HCT for testicular cancer to Aetna, review your documentation standards against these updated criteria before submitting claims.

Quick-Reference Table

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The updated CPB 0617 Aetna coverage policy covers autologous HCT for testicular cancer in three specific clinical situations. Each one ties coverage to where the patient is in their treatment course and how they responded to initial chemotherapy.

Covered indication 1: Refractory disease after first-line chemo. Aetna considers autologous HCT medically necessary when a patient does not reach complete remission after an initial course of standard-dose chemotherapy. That includes two subgroups: patients with refractory disease (less than 50% reduction in tumor burden) and patients with a partial response (at least 50% reduction in tumor burden). Document which category applies in every clinical note attached to CPT 38241 claims.

Covered indication 2: Relapse after first-line chemo. Autologous HCT as consolidation therapy is covered when a patient relapses after completing an initial course of standard-dose chemotherapy. This is a distinct clinical scenario from indication one. Your documentation needs to show the prior treatment course, the response, and the relapse event — not just the current treatment plan.

Covered indication 3: Tandem transplant after relapse. Aetna recognizes tandem autologous HCT as medically necessary for patients with testicular cancer who have relapsed. This is the most aggressive of the three covered approaches. Tandem transplants typically involve two sequential high-dose chemotherapy cycles each followed by stem cell reinfusion. Make sure your charge capture reflects both transplant episodes and the full 38206–38241 code set as appropriate.

All three covered indications apply specifically to autologous transplantation — the patient's own stem cells. Allogeneic transplantation (donor cells) is a different story. See the exclusions section below.

Prior authorization is not explicitly detailed within CPB 0617 itself, but HCT procedures at this clinical complexity almost always require prior auth under Aetna plans. Confirm prior authorization requirements with Aetna before scheduling any transplant. A claim denial on a high-cost procedure like HCT is expensive to work — prevention is cheaper.

Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

Two scenarios land in Aetna's experimental, investigational, or unproven category. They're not edge cases. Both are situations oncology billing teams encounter regularly.

Autologous HCT as initial treatment. If a provider wants to use autologous HCT instead of standard-dose chemotherapy as first-line treatment for testicular cancer, Aetna will not cover it. The policy is explicit: the patient must first complete a course of standard-dose chemotherapy using FDA-approved drugs. Skipping that step makes the transplant non-covered, regardless of clinical rationale.

Allogeneic HCT for any testicular cancer indication. Aetna classifies all allogeneic hematopoietic cell transplantation for testicular cancer as experimental. There are no covered allogeneic indications under this policy. If your program has Aetna members receiving allogeneic transplants for testicular cancer, loop in your compliance officer before billing. A denial on a six-figure claim is not a routine AR problem.

Coverage Indications at a Glance

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025

The effective date for CPB 0617 is December 5, 2025. Here's what to do now.

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0617

Covered CPT Codes (When Selection Criteria Are Met)

These codes are covered when the medical necessity criteria in CPB 0617 are met. Document the applicable covered indication for every claim.

The policy data includes 97 additional chemotherapy administration CPT codes (96401–96549 range) covered under the same criteria. Review the full CPB 0617 policy at app.payerpolicy.org/p/aetna/0617 for the complete code list.

Key ICD-10-CM Diagnosis Codes

The policy data includes 94 ICD-10-CM codes. The full list is available in CPB 0617. The policy data provided does not include individual code descriptions for the complete ICD-10 set — pull the full code list directly from the source to build your charge capture mapping.

Access the complete ICD-10-CM code list at app.payerpolicy.org/p/aetna/0617.

A Note on the Chemotherapy Code Range

The breadth of the 96401-range chemotherapy administration codes in CPB 0617 makes sense — HCT for testicular cancer involves high-dose conditioning chemotherapy before the transplant. These codes cover the chemo administration that precedes the actual stem cell reinfusion captured by 38241. Make sure your billing team maps each part of the treatment episode to the right code. Bundling errors between the chemo prep and the transplant itself are a common source of claim denial in HCT billing.